Beta-thalassemia (B-thal) Market
- 2026 年市場規模
- USD 600 Mn
- 2033 年預估規模
- USD 1,040 Mn
- 年複合成長率 CAGR
- 8.1%
以上數字由 Coherent Market Insights 於本報告中提出，量子訊息原樣引用。
授權報價
| Single User Price | $4,500 USD |
| Enterprise License | $10,000 USD |
完整報告名稱與涵蓋範圍
Beta-thalassemia (B-thal) Market, By Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy, Others), By Disease Indication (Beta Thalassemia Minor, Beta Thalassemia Intermedia, Beta Thalassemia Major), By Geography (North America, Latin America, Europe, Asia Pacific, Middle East & Africa)
報告摘要
Thalassemia is a term for a group of disorders in which there is reduced levels of hemoglobin, decreased red blood cell production and anemia. There are two main forms – alpha thalassemia and beta thalassemia, each with various subtypes. Beta thalassemia minor, also known as beta thalassemia trait, is a common condition. The symptoms and severity of beta thalassemia varies greatly from one person to another. Individuals with beta thalassemia minor do not develop symptoms of the disorder but may have a mild anemia. Several individuals with beta thalassemia minor go through life never knowing they carry an altered gene for the disorder. A beta thalassemia major diagnosis is usually made during the first two years of life and individuals require regular blood transfusions and lifelong medical care to survive. When the disorder develops later during life, a diagnosis of beta thalassemia intermedia is given; individuals may only require blood transfusions on rare, specific instances. Most beta thalassemia cases are caused by a mutation in the HBB gene. In extremely rare cases, a loss of genetic material (deletion) that includes the HBB gene causes the disorder. Genes provide instructions for creating proteins that play a critical role in many body functions. When a gene mutation occurs, the protein product may be faulty, inefficient, or absent. Depending upon the functions of the particular protein, this can affect several organ systems of the body. Individuals with beta thalassemia minor have a mutation in one HBB gene and are carriers for the disorder. Individuals with beta thalassemia intermedia or major have mutations in both HBB genes.
Market Dynamics
The increasing incidence of beta thalassemia, rising research and development activities for the development of novel therapeutics for the treatment of beta thalassemia, and increasing adoption of inorganic growth strategies such as acquisitions and collaborations by key players operating in the market, are the major factors that are expected to drive growth of the global beta-thalassemia (B-thal) market over the forecast period.
For instance, in April 2018, GSK, a global pharmaceutical company and Orchard Therapeutics, a pharmaceutical company, entered into a strategic agreement under which GSK will transfer its portfolio of approved and investigational rare disease gene therapies to Orchard. This acquisition strengthens Orchard’s position as a global leader in gene therapy for rare diseases. GSK will continue to invest in the development of its platform capabilities in cell and gene therapies, with a focus on oncology.
Moreover, the portfolio of gene therapy programs Orchard had acquired includes, Strimvelis, the first autologous ex vivo gene therapy for children with adenosine deaminase severe combined immunodeficiency (ADA-SCID), approved by the EMA in 2016, two late-stage clinical programs in ongoing registration studies for metachromatic leukodystrophy (MLD) and Wiskott Aldrich syndrome (WAS), and one clinical program for beta thalassemia.
Key features of the study
• This report provides in-depth analysis of the global beta-thalassemia (B-thal) market, and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2026–2033), considering 2025 as the base year
• It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
• This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
• It profiles key players in the global beta-thalassemia (B-thal) market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
• Key companies covered as a part of this study include Celgene Corp., BlueBird Bio, Protagonist Therapeutics, Agios Pharmaceuticals, Ionis Pharmaceuticals, Vifor Pharma, Orchard Therapeutics, Sangamo Therapeutics, CRISPR Therapeutics, DisperSol Technologies, Kiadis Pharma, Incyte Corporation, Editas Medicine, Global Blood Therapeutics, and Syros Pharmaceuticals
• Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
• The global beta-thalassemia (B-thal) market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
• Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global beta-thalassemia (B-thal) market
Market Segmentation
• By Treatment (Revenue, USD Mn, 2021-2033)
o Iron Chelating Drugs
o Erythroid Maturation Agents
o Stem Cell Therapy
o Others
• By Disease Indication (Revenue, USD Mn, 2021-2033)
o Beta Thalassemia Minor
o Beta Thalassemia Intermedia
o Beta Thalassemia Major
• By Region (Revenue, USD Mn, 2021-2033)
o North America
U.S.
Canada
o Latin America
Brazil
Mexico
Argentina
Rest of Latin America
o Europe
Germany
U.K.
France
Italy
Spain
Russia
Rest of Europe
o Asia Pacific
China
India
Japan
Australia
South Korea
ASEAN
Rest of Asia Pacific
o Middle East
GCC
Israel
Rest of Middle East
o Africa
South Africa
Central Africa
North Africa
• Key Players
o Celgene Corp.
o BlueBird Bio
o Protagonist Therapeutics
o Agios Pharmaceuticals
o Ionis Pharmaceuticals
o Vifor Pharma
o Orchard Therapeutics
o Sangamo Therapeutics
o CRISPR Therapeutics
o DisperSol Technologies
o Kiadis Pharma
o Incyte Corporation
o Editas Medicine
o Global Blood Therapeutics
o Syros Pharmaceuticals
目錄 Table of Contents
Table of Contents
1. Research Objectives and Assumptions
o Research Objectives
o Assumptions
o Abbreviations
2. Market Overview
o Report Description
Market Definition and Scope
o Executive Summary
Market Snapshot, By Treatment
Market Snapshot, By Disease Indication
Market Snapshot, By Region
o Coherent Opportunity Map (COM)
3. Market Dynamics, Regulations, and Trends Analysis
o Market Dynamics
Drivers
Restraints
Market Opportunities
o Impact Analysis
o Market Trends
o Key Developments
o Product Approval
o Collaboration/Merge/Acquisition
o Regulatory Landscape
o PEST Analysis
o Porter’s Five Forces Analysis
o Epidemiology
o Robust Pipeline Analysis
4. Global Beta-thalassemia (B-thal) Market, By Treatment, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Iron Chelating Drugs
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Erythroid Maturation Agents
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Stem Cell Therapy
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Others
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
5. Global Beta-thalassemia (B-thal) Market, By Disease Indication, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, 2026 and 2033 (%)
Y-o-Y Growth Analysis, 2022– 2033
Segment Trends
o Beta Thalassemia Minor
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Beta Thalassemia Intermedia
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
o Beta Thalassemia Major
Introduction
Market Size and Forecast, and Y-o-Y Growth, 2021-2033, (USD Million)
6. Global Beta-thalassemia (B-thal) Market, By Region, 2021 – 2033, (USD Million)
o Introduction
Market Share Analysis, By Region, 2026 and 2033 (%)
Y-o-Y Growth Analysis, For Regions, 2022–2033
Regional Trends
o North America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o U.S.
o Canada
o Latin America
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o Brazil
o Mexico
o Argentina
o Rest of Latin America
o Europe
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o U.K.
o Germany
o Italy
o France
o Spain
o Russia
o Rest of Europe
o Asia Pacific
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o China
o India
o Japan
o ASEAN
o Australia
o South Korea
o Rest of Asia Pacific
o Middle East
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country, 2021 – 2033, (USD Million)
o GCC
o Israel
o Rest of Middle East
o Africa
Introduction
Market Size and Forecast, and Y-o-Y Growth, By Treatment, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Disease Indication, 2021 - 2033, (USD Million)
Market Size and Forecast, and Y-o-Y Growth, By Country/Region, 2021 – 2033, (USD Million)
o North Africa
o Central Africa
o South Africa
7. Competitive Landscape
o Heat Map Analysis
o Market Share Analysis
Company Profile
o Celgene Corp.
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
BlueBird Bio
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Protagonist Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Agios Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Ionis Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Vifor Pharma
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Orchard Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Sangamo Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
CRISPR Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
DisperSol Technologies
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Kiadis Pharma
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Incyte Corporation
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Editas Medicine
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Global Blood Therapeutics
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
Syros Pharmaceuticals
o Company Highlights
o Product Portfolio
o Financial Performance
o Recent Highlights
o Market Strategies
o Analyst Views
8. Section
o References
o Research Methodology
o About Us
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 Coherent Market Insights 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們